PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-11.18%
Both yoy net incomes decline, with VET at -181.20%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
8.81%
Some D&A expansion while VET is negative at -4.31%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
1521.43%
Some yoy growth while VET is negative at -85.35%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
303.33%
SBC growth while VET is negative at -7.47%. John Neff would see competitor possibly controlling share issuance more tightly.
175.97%
Well above VET's 178.27% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
-203.03%
AR is negative yoy while VET is 0.00%. Joel Greenblatt would see a short-term cash advantage if revenue remains unaffected vs. competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
181.48%
Growth well above VET's 178.27%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
332.00%
Well above VET's 156.98%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
63.76%
Operating cash flow growth above 1.5x VET's 9.80%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
-13.98%
Both yoy lines negative, with VET at -87.68%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
678.75%
Acquisition growth of 678.75% while VET is zero at 0.00%. Bruce Berkowitz sees a mild outflow that must deliver synergy to justify the difference.
13.98%
Purchases growth of 13.98% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
-41.67%
We reduce yoy sales while VET is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
-13.98%
We reduce yoy other investing while VET is 194.20%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
152.73%
We have mild expansions while VET is negative at -40.48%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
12.50%
We repay more while VET is negative at -8.35%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.